Lumosa Therapeutics Co Ltd (6535):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Lumosa Therapeutics Co Ltd (6535) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8021
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Lumosa Therapeutics Co Ltd (Lumosa Therapeutics) is a developer of drugs for the treatment of neurological and inflammatory diseases. The company’s pipeline products include LT-1001, an analgesic injection for severe pain relief; and LT-3001, a novel small molecule for acute ischemic stroke. Its activities comprise chemical development, translational research, preclinical, intellectual property, regulatory affairs, clinical development, project management and business development. Lumosa Therapeutics’s translational research services include disease model development, in vitro biassay development, acute toxicity pilot evaluation, bioanalytical method development, product stability analysis, compound purity analysis, and others. The company partners with biotech and pharmaceutical companies for product licensing, development and commercialization. Lumosa Therapeutics is headquartered in Taipei, Taiwan.

Lumosa Therapeutics Co Ltd (6535) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Lumosa Therapeutics Enters into Agreement with Camargo Pharma 10
Licensing Agreements 11
InteRx Biomedical Enters into Licensing Agreement with Lumosa Therapeutics 11
Equity Offering 12
Lumosa Therapeutics to Raise USD14.5 Million in Public Offering of Shares 12
Shundu Therapeutics Raises Funds through Private Placement 13
Lumosa Therapeutics Co Ltd – Key Competitors 14
Lumosa Therapeutics Co Ltd – Key Employees 15
Lumosa Therapeutics Co Ltd – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Product News 17
03/14/2017: Lumosa’s LT1001 Approved in Taiwan 17
Product Approvals 18
Aug 28, 2017: Lumosa Therapeutics Partners with Camargo Pharmaceutical Services in the Development of Naldebain in the US 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lumosa Therapeutics Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lumosa Therapeutics Enters into Agreement with Camargo Pharma 10
InteRx Biomedical Enters into Licensing Agreement with Lumosa Therapeutics 11
Lumosa Therapeutics to Raise USD14.5 Million in Public Offering of Shares 12
Shundu Therapeutics Raises Funds through Private Placement 13
Lumosa Therapeutics Co Ltd, Key Competitors 14
Lumosa Therapeutics Co Ltd, Key Employees 15

List of Figures
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lumosa Therapeutics Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Lumosa Therapeutics Co Ltd (6535):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • N Brown Group plc:企業の戦略・SWOT・財務情報
    N Brown Group plc - Strategy, SWOT and Corporate Finance Report Summary N Brown Group plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • RRB Energy Ltd:企業の戦略的SWOT分析
    RRB Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Tchibo GmbH (Foodservice):企業の戦略・SWOT・財務情報
    Tchibo GmbH (Foodservice) - Strategy, SWOT and Corporate Finance Report Summary Tchibo GmbH (Foodservice) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Medigen Vaccine Biologics Corp (6547):製薬・医療:M&Aディール及び事業提携情報
    Summary Medigen Vaccine Biologics Corp (MVC) a subsidiary of Medigen Biotechnology Corp is a biopharmaceutical company with focus on the development and production of vaccines and biologics. Its research and development pipeline includes EV71 vaccine to prevent enterovirus infection; H5N1 and H7N9 m …
  • PayPal Holdings Inc:企業の戦略・SWOT・財務分析
    PayPal Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary PayPal Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • 99 Cents Only Stores LLC:企業の戦略的SWOT分析
    99 Cents Only Stores LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Ascent Solar Technologies Inc (ASTI):企業の財務・戦略的SWOT分析
    Ascent Solar Technologies Inc (ASTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Cara Therapeutics Inc (CARA)-医療機器分野:企業M&A・提携分析
    Summary Cara Therapeutics Inc (Cara Therapeutics) is a clinical-stage biotechnology company that develops novel therapeutics for pain and inflammation and pruritus. The company products include kappa receptor agonists and cannabinoid receptors. It offers products for therapeutic areas which include …
  • Alimera Sciences Inc (ALIM):企業の財務・戦略的SWOT分析
    Alimera Sciences Inc (ALIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Maxim Power Corp. (MXG):企業の財務・戦略的SWOT分析
    Maxim Power Corp. (MXG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Zynex Inc (ZYXI):医療機器:M&Aディール及び事業提携情報
    Summary Zynex Inc (Zynex), formerly Zynex Medical Inc is a medical technology company that designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. The company’s products include NexWave, a dual channel, multi-modality interferential current, tra …
  • Arise AB (ARISE)-エネルギー分野:企業M&A・提携分析
    Summary Arise AB (Arise) is an independent onshore wind company. It has a presence in the entire value chain from prospecting and permit management to financing, construction, sale, and long-term management of its own and others’ wind farms. The company owns wind plants in southern Sweden; and co-ow …
  • JCR Pharmaceuticals Co Ltd (4552):企業の財務・戦略的SWOT分析
    JCR Pharmaceuticals Co Ltd (4552) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • MEI Pharma Inc (MEIP):企業の財務・戦略的SWOT分析
    MEI Pharma Inc (MEIP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Actelion Pharmaceuticals Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Actelion Pharmaceuticals Ltd (Actelion), subsidiary of Johnson & Johnson is a biopharmaceutical company, which discovers, develops and commercializes innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development of treatments for pulmonary a …
  • Rosoboronexport:企業の戦略・SWOT・財務情報
    Rosoboronexport - Strategy, SWOT and Corporate Finance Report Summary Rosoboronexport - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • WEG SA:企業の戦略・SWOT・財務情報
    WEG SA - Strategy, SWOT and Corporate Finance Report Summary WEG SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • VLP Therapeutics LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary VLP Therapeutics LLC (VLP) is a biopharmaceutical company that develops therapeutic vaccines and next generation of targeted antibody agents to address global unmet medical needs. The company offers product such as vaccines for the treatment of cancer types such as breast, lung, prostate can …
  • Flex Ltd (FLEX):医療機器:M&Aディール及び事業提携情報
    Summary Flex Ltd (Flex) provides design, engineering, manufacturing, and supply chain services to electronics original equipment manufacturers. The company, through its Sketch-to-Scale concept, provides concept design, prototype creation, intellectual property protection, new product introduction, a …
  • China Sunergy Co., Ltd.:企業の戦略的SWOT分析
    China Sunergy Co., Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆